Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:07 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer returning or spreading, and Moderna shares closing 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:02 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the treatment plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst and improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:57 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:52 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:47 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing longer time without cancer recurrence when combined with Keytruda. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:42 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:37 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing longer recurrence-free survival when combined with Keytruda. The stock surged 177%, indicating a material positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:27 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:22 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 03:17 AM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive catalyst.